,126 Given the complex and overlapping pathologies in most neurodegenerative diseases, the logical next step in disease-modifying therapy is the adoption of combination approaches.127, 128, 129 Combination therapies can simultaneously target multiple pathological proteins (such as amyloid β, tau, α-synuclein, and TDP-43) and modulate neuroinflammation, addressing the multifactorial nature of these disorders.127, 128, 129. This evidence concerns the gene MAPT and neurodegenerative disease.